Trump official credited for drug-pricing negotiations advances to

Senate Democrats spent the hearing trying to paint Chris Klomp as some kind of pharmaceutical industry insider. Their actual complaint? That he helped the Trump administration strike deals with drugmakers to lower prices. Read that back to yourself. The criticism is that he was too good at negotiating against the very companies the left claims to distrust. It's a strange hill to die on, unless the goal is to make sure nothing ever actually gets done.

The durable reality here is that the administration got results. Real agreements were reached. Prices went down for people who needed relief. And now the Senate Finance Committee approved him anyway, which suggests the theatrics are wearing thin even in Washington. We should give credit where it's earned: this is what getting results for patients looks like, not just holding hearings about it. The Democrats' preferred approach seems to be keeping the issue alive forever, as long as it never gets solved.

Klomp's next job, if confirmed, puts him right where the action is on Medicare and Medicaid. That's a position where competence matters more than ideological purity. His confirmation would be a repudiation of the idea that you need to be hostile to the entire healthcare industry to be serious about reform. You can be tough at the table while still knowing how the room works. That's how you get the deals done in the first place.

Maybe the real concern from the other side is that he might succeed again. The "cozy with pharma" line falls apart pretty quickly when the proof of his work is saving seniors money on their prescriptions. We'll take that outcome over another committee lecture about corporate greed every single time.